Use of Convalescent Plasma for COVID-19
Use of Convalescent Plasma for COVID-19
The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe
 whether this will result in a significant improvement in clinical outcome in comparison to
 historical experience.
Inclusion Criteria:

 -  Documented COVID-19 infection by nasal pharyngeal sampling

 -  COVID-19 disease falling into one of the following groups:

 -  Critical disease: respiratory failure requiring mechanical ventilation, pressor
 support, or multiple organ dysfunction/failure

 -  Severe disease: tachypnea >/=30 per min, O2 sats </=93% at rest, PaO2/FiO2 index
 </=300mmHg

 -  High Risk: upper respiratory symptoms but no radiographic evidence of disease,
 immunocompromised, insulin-dependent diabetes, poorly controlled HIV disease, moderate
 to severe asthma history, severe COPD, morbid obesity (BMI >/=40, age >/=65 years

 -  Health Care Providers: health care providers at risk to exposure to COVID-19 infection
 or those with mild to non-severe disease

 Exclusion Criteria:

 -  History of IgA deficiency

 -  History of anaphylatic reaction to blood product transfusion including
 hypersensitivity to immunoglobulin therapy